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Abstract
Purinergic receptors play important roles in central nervous system (CNS). These receptors are involved in cellular neuroin-
flammatory responses that regulate functions of neurons, microglial and astrocytes. Based on their endogenous ligands, purinergic
receptors are classified into P1 or adenosine, P2X and P2Y receptors. During brain injury or under pathological conditions, rapid
diffusion of extracellular adenosine triphosphate (ATP) or uridine triphosphate (UTP) from the damaged cells, promote microglial
activation that result in the changes in expression of several of these receptors in the brain.
Imaging of the purinergic receptors with selective Positron Emission Tomography (PET) radioligands has advanced our
understanding of the functional roles of some of these receptors in healthy and diseased brains. In this review, we have accu-
mulated a list of currently available PET radioligands of the purinergic receptors that are used to elucidate the receptor functions
and participations in CNS disorders. We have also reviewed receptors lacking radiotracer, laying the foundation for future
discoveries of novel PET radioligands to reveal these receptors roles in CNS disorders.
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Introduction
The cell surface purinergic receptors (purinoceptors) are
plasma membrane proteins found in nearly all mammalian tis-
sues including the central nervous system (CNS).1 The history
of the purinergic receptors goes back to early 20th century
when, for the first time, an observation was made that purines
effected cardiovascular physiology.2 Almost half a century
later, these receptors were classified based on their endogenous
ligands into P1 and P2 categories.3
P1 or adenosine receptors (ARs) are a family of G protein–
coupled receptors (GPCRs) with 4 subtypes: A1, A2A, A2B,
and A3. P2 receptors are subgrouped into the ligand-gated ion
channel receptors P2X with 7 receptor subtypes: P2X1, P2X2,
P2X3, P2X4, P2X5, P2X6, P2X7, and P2Y, which are G
protein-coupled metabotropic receptors with 8 subtypes:
P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14
(Figure 1).4 Burnstock has recently published an excellent
review article on purinergic receptors, their distributions, and
functions revealing the importance of these receptors in phy-
siological system.5 Purinergic receptors play major roles in
CNS disorders including Alzheimer disease (AD), Parkinson
disease (PD), Huntington disease (HD), frontotemporal
dementia (FD), amyotrophic lateral sclerosis (ALS), multiple
scleroses (MS), traumatic brain injury (TBI), stroke, cerebral
ischemia, epilepsy, psychiatric diseases, sleep disorder, and
neuropathic pain.1,3,6,7
In the CNS, adenosine 50-triphosphate (ATP), an energy
source for neurons and glial cells, also acts as an extracel-
lular purinergic signaling molecule that controls communi-
cation between brain cells.8 The steady state concentration
of cytosolic ATP is high, ranging between 5 and 10 mM,
and very low (nM) in the extracellular space.9 Under patho-
logical conditions and CNS insults such as trauma, ischemic
stroke, epileptogenic seizures, cellular stress, neuroinflam-
mation, and neurodegenerative disorders, high concentration
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of ATP is released to the extracellular region as a danger
signal creating a cascade of events that eventually damages
the neurons.10,11
High level of extracellular ATP from the damaged cells
enforces microglia to undergo chemotaxis to the site of injury
in order to remove cell debris from these sites.12 Microglial
activation13 results in upregulation of P2X4 and P2X7
14,15 and
downregulation of P2Y12 receptor expression.
16 This balance
between the expression of P2X4, P2X7, and P2Y12 receptors
dictate the destiny of microglia.17 A relative expression levels
of P2X4 and P2X7 receptors are positive indicator of microglial
activation, while P2Y12 receptor is a negative predictor.
18
Additionally, upon release of the large amount of ATP (hun-
dreds of mmol), P2Y1 and P2X7 receptors facilitate movement
of ramified microglia to the damage site, while P2Y6 receptor,
a normally expressed receptor on the activated microglia, inter-
venes the process of phagocytosis.3,19 Furthermore, extracellu-
lar ATP can be converted to adenosine via ectonucleotidases
CD39 and CD73 that are present in microglia20 and in turn
activates ARs as well.21,22
While novel ligands of some purinergic receptors are cur-
rently used as pharmacological tools to define and modify
actions of these receptor subtypes in the CNS,23 there is still
a growing need to clearly understand these receptors’ roles in
the brain, specifically as it relates to neuroinflammation and
neurodegeneration. Positron emission tomography (PET) ima-
ging has advanced our understanding of the functions of pur-
inergic receptors in healthy and pathological brains.24,25
Herein, we have reviewed the significance of the purinergic
receptors in the CNS and accumulated a comprehensive list
of the existing PET radioligands that have been used as tools
for understanding the functions of these receptors.
Adenosine, Receptors and Functions in the
CNS
Adenosine has been widely recognized as an inhibitory mod-
ulator of the CNS.26 It acts as a homeostatic modulator at
synapses26,27 and participates in neurotransmitter release,28
neuronal excitability, synaptic plasticity,29 and local inflamma-
tory processes.30,31 Adenosine is complicated in neurobiology
of learning and memory29,32,33 by overstimulating the
N-methyl-D-aspartic acid (NMDA) receptors34,35 that influence
long-term potentiation (LTP) and long-term depression
(LTD).29 Additionally, adenosine participates in modulation
of neurotransmissions exerted by dopamine (DA) and acetyl-
choline (Ach).36-48 Consumption of drugs of abuse and psy-
chostimulants, either acutely or chronically, has shown to
modify adenosine level in the brain.49 As such, a more clear
understanding of the involvement of adenosine signaling path-
way during addiction might help to explore potential treatments
for substance use dependence.50 Several reports have indicated
the involvement of adenosine in neuropathological conditions
including stroke,51,52 epilepsy,53 PD,54-57 and other neurode-
generation disorders.31
Extracellular adenosine binds to its 4 receptor subtypes A1,
A2A, A2B, and A3 to exert its effect in the CNS.
30 A1R and
A2AR have high affinities of 70 and 150 nM, respectively,
while A2BR and A3R have a distinctly lower affinities of
5100 and 6500 nM, respectively, for adenosine.58 All ARs are
Figure 1. Purinergic receptor subfamilies and their endogenous ligands.
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present on neurons,52 astrocytes,59 oligodendrocytes,60 and
microglia.61
In the brain, A1 and A2A are the major ARs.
58 A1 receptor,
the most abundant subtype, is widely distributed in the cortex,
hippocampus, and cerebellum, while A2A receptor is mainly
localized in the striatum and olfactory bulb.30 Presynaptically,
A1 and A2A interact with adenosine to modulate the release of
neurotransmitters.62 Postsynaptically, adenosine decreases cel-
lular excitability through activation of A1Rs or inhibition of
A2ARs.
63 Thus, A1Rs impose an inhibitory brake on excitatory
transmission, while A2A receptors engage in promoting excita-
tory effect.64 In general, A1R is considered a neuroprotective
and A2A receptor is designated as a neurodegenerative recep-
tor.65 Consequently, adenosine mainly effects brain functions
through interaction with these 2 receptors, A1 and A2A,
64 and a
fine balance between inhibitory action of A1 and excitatory
function of A2A receptors influences the neuromodulatory
effect of adenosine.
Adenosine receptors undergo different activities during
neurodegeneration progression.66 While both A1 and A2A
receptors have shown upregulation in the frontal cortex,67 the
A1R expression was reduced in hippocampus, specifically in
dentate gyrus, and in CA1, but not in CA3 region.68 Addition-
ally, studies of brain of patients with AD have revealed reduc-
tion of striatal A1Rs in this population.
31 Several studies have
shown that both A1R and A2AR may be involved in metabo-
lism of amyloid b (Ab) protein and A1 agonists and A2A
antagonists might serve as an effective therapy for treating
patients with AD.69,70 Moreover, there are some evidences
that support the cross talk between A1Rs and A2ARs in other
age-related disorders.71-73
Both A1 and A2A receptors are also expressed in endothelial
cells of the primary human brain, suggesting that modulation of
these receptors can alter blood–brain barrier (BBB) and result
in abnormal brain permeability that could interfere with drug
delivery into the CNS.74
Provided the roles of A1 and A2A receptors in brain pathol-
ogies, the availability of scientific tools such as specific PET
radioligands for evaluation of these receptors functions under
normal and pathophysiological conditions would be desirable
and could help elucidate novel therapeutic strategies.75
Adenosine A1R and Functions in the CNS
A1 is the most abundant AR subtype in the brain with broad
distribution in neurons of the cortex, hippocampus, and cere-
bellum.31,58 Several studies have shown that activation of ade-
nosine A1R promoted neuroprotection, induced sedation,
reduced anxiety, inhibited seizures,76 and reduced A1R exacer-
bated neuronal damage.58 Significant reduction in A1R expres-
sion was detected in layers of the dentate gyrus in the brain of
AD subjects,68,77 providing evidence that A1R agonists might
be an effective therapy for treatment of AD even at late stages
of the disease.78 Additionally, A1R agonists or adenosine reup-
take inhibitors have shown to decrease the extent of brain dam-
age in most brain injuries.78,79 There are evidences of increased
microglial proliferation; enhanced matrix metalloproteinase 12
(MMP-12) expression, inducible nitric oxide synthase, and pro-
inflammatory interleukin-1b (IL-1b); and exacerbated demye-
lination in MS and neuronal injury in A1R knockdown animal
models.80,81 The positive effect of A1Rs activation in the CNS
suggests that this receptor could be one of the most promising
targets for the development of novel drugs with neuroprotec-
tive effect for the treatment of neurological and psychiatric
disorders.69
Several A1R agonist have been reported to date; most of
them have only minimal brain penetration. A nonselective ago-
nist MRS5474 has shown antidepressant and anticonvulsant
activities.82 While not optimum to fully map all the functions
of the A1R in the brain, several
11C and 18F PET radioligands of
the receptor have been evaluated for imaging of the A1R in the
brain as described herein.
[11C] PET radioligands of adenosine A1R. As shown in Figure 2,
several 11C PET radioligands of the A1R have been developed
and tested thus far. The first PET radiotracer was developed by
11C radiolabeling of the xanthene-derived A1R antagonist
KF15372, [11C]KF15372, and showed a specific and reversible
brain uptake but an unacceptable high fraction of nonspecific
binding that limited its use in preclinical evaluation of the
A1R.
83,84 [11C]MPDX, another analog of A1R antagonist
KF15372, was developed to measure regional A1R densities
in the brain of rodent and in patients with diffuse axonal injury,
a model for TBI.85 It detected an increase in A1R expression in
Figure 2. Structures of the adenosine A1 receptor [
11C] PET radioligands: [11C]KF15372, [11C]MPDX, [11C]FR194921, and [11C]MMPD. PET
indicates positron emission tomography.
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areas surrounding the injuries in the brain, emphasizing on
neuroprotective and neuromodulatory effects of A1R in TBI.
85
Moreover, [11C]MPDX was also used to investigate the cere-
bral density of A1Rs in early stages of PD and showed a higher
binding potential in the temporal lobe of the patients with PD
compared to the healthy controls.86 Similarly, [11C]MPDX was
used for mapping of the A1Rs in the brain of aged human
compared to the young subjects and showed a significantly
lower BPND in the frontal, temporal, occipital, parietal cortices,
and thalamus of aged subjects.87 [11C]MPDX is currently the
most widely used PET agent for imaging the A1Rs in human
brain.83,85 Interestingly, [11C]MPDX was employed to identify
the selective antagonists (DPCPX and caffeine) and agonist
(N6-cyclopentyladenosine [CPA]) binding sites on the A1Rs
and suggested that different ligands (agonists and/or antago-
nists) bind to A1Rs allosterically.
88
The first nonxanthine 11C PET ligand of A1 R was
[11C]FR194921, an analog of a potent A1R antagonist
FR194921 (Ki ¼ 2.9 nM).89,90 The PET imaging with
[11C]FR194921 showed selective accumulation of A1Rs in the
hippocampus, cerebral cortex, striatum, thalamus, and cerebel-
lum of the rat brain.89 However, the specific binding of
[11C]FR194921 was not as high as expected.89 Recently, a
highly potent partial A1R agonist 2-amino-4-(3-methoxyphe-
nyl)-6-(((6-methylpyridine-2-yl)methyl)thio)pyridine-3,5-
dicarbonitrile was labeled with 11C to produce [11C]MMPD
and showed brain uptake that was consistent with A1R.
91
[11C]MMPD is currently under further evaluation for partici-
pation of A1R in sleep mechanisms.
91
[18F] PET radioligands of adenosine A1R. Few
18F PET radioli-
gands have been developed and evaluated for imaging of the
A1R as shown in Figure 3. Of these, [
18F]CPFPX has shown
high affinity and selectivity for A1R
6,92; however, due to the
high in vivo metabolism, this radiotracer exhibited a short bio-
logical half-life of only about 10 minutes.84 Despite this fact,
[18F]CPFPX has been used for imaging of A1Rs in the human
brain93 and is currently a standard PET radioligand for evalua-
tion of the A1R density in CNS disorders such as sleep–wake
research.84,94-96
In order to improve metabolic stability inherent in
[18F]CPFPX, two additional fluorinated PET analogs
[18F]CBCPM and [18F]CPMMCB were developed and
tested.84 In vitro autoradiographic studies of rat brain slices
with [18F]CBCPM and [18F]CPMMCB revealed accumulation
of both compounds in regions known to have a high A1R
expression. However, in vitro metabolite studies using human
liver microsomes identified comparable metabolic instabilities
for these radioligands, similar to that of the parent ligand
[18F]CPFPX.84
Importantly, both [11C]MPDX or [18F]CPFPX are inverse
agonist of the A1R. [
11C]MPDX did not compete with either
endogenous or exogenous agonist in receptor binding but did
show an increased binding potential without enhanced tracer
delivery to the brain.88 Despite stated limitations, these tra-
cers85 have presented promising imaging tools for mapping
of A1R in the brain
86,87,96. A list of all aforementioned A1R
PET radioligands is presented in Table 1.
Adenosine A2AR and Functions in the CNS
Highly expressed in the basal ganglia, A2ARs specially reside
on GABAergic neurons of the striatum.58 These receptors are
also expressed at low level in hippocampus, cortex, and other
brain regions, and the extrastriatal increase in A2ARs has been
detected in pathological challenge models and animal models
of neuroinflammation.97 Several studies have revealed an
increased level of A2AR expression in hippocampal neurons
of patients with AD and in animal models of cognition.98,99
The same studies reported that inhibition or genetic deletion of
A2A receptors enhanced memory function in the brain.
100 A2A
receptors are also expressed in areas of the brain that is rich in
DA,101 providing a possibility of being considered as a target
for developing drugs that prevent addiction.102
Inhibition of A2AR has resulted in a complete shift of LTD
to LTP, supporting a major role of A2ARs in cognitive defi-
cits.103 Inhibition of A2AR has also been promising in reduction
of excitotoxicity in neurons104,105 and in movement diminished
motor symptoms in PD.54,55,106-111 Additionally, in vitro stud-
ies of A2AR antagonists have shown to prevent Ab-induced
neurotoxicity and synaptotoxicity,99,100 while A2A receptor
Figure 3. Structures of the adenosine A1 receptor [
18F] PET radioligands: [18F]CPFPX, [18F]CBCPM, and [18F]CPMMCB. PET indicates positron
emission tomography.
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agonists increased Ab production.100 However, study of APP/
PS1 mice treated with A2A receptor antagonist istradefylline,
an anti-Parkinson drug, showed an increase in Ab42 accumula-
tion in cortical, but not in the hippocampal neurons.112 The
underlying relationship between amyloid deposition, AD pro-
gression, and adenosine remains unclear and require more clar-
ification.97,113,114 Nevertheless, there is an indication that
activation A2A receptor can result in microglia activation and
antagonists of A2A receptor can reverse this process.
115 Some
studies have suggested that A2A receptor inhibition might also
contribute to control of astrogliosis as well,116 and selective
elimination of A2A receptors from astrocytes has resulted in
memory improvement in animal models of AD.113 Therefore,
in addition to microglia, astrocytes might also be a responsible
culprit, associating A2A receptor with neuroinflammatory and
neurodegenerative diseases.
Interestingly, excitotoxicity prevention by the A2A receptor
antagonist appears to be time dependent, and while A2A recep-
tor antagonist SCH58261 completely blocked the induced glu-
tamate release in rat striatum,117 its effect was reversed 2 weeks
after the treatment.105 Remarkably, this spontaneous glutamate
release in response to SCH58261 treatment was different in
young rats compared to the aged ones.104 Additionally, recent
study suggested that, although A2A receptor antagonists ini-
tially protected against transient ischemic injury, this protec-
tive effect disappeared 7 days after ischemia and despite
continued treatment with the antagonist.118
Application of pharmacological tools of the A2A receptors
have shown a significant benefit in treating several CNS dis-
orders,119 and thus, PET imaging of the A2A receptors has been
useful to study in vivo expression of A2A receptors in normal
and under pathophysiological brains.
[11C] PET radio ligands of adenosine A2AR. Several
11C radioli-
gands of the A2R have been developed for PET imaging of this
receptor as shown in Figure 4. These most studied ligands are 2
xanthine-derived compounds, [11C]TMSX ([11C]KF18446)
and [11C]KF21213, and 2 nonxanthene compounds,
[11C]SCH442416 and [11C]Preladenant.25 Within the
xanthene-based PETs, [11C]TMSX has been successfully eval-
uated in vivo in rodent (mice and rat) and in nonhuman primate
(monkeys) and has detected A2ARs in the brain with good
striatum/cerebellum uptake ratio in the above animal spe-
cies.25,120-122 Another xanthine PET ligand [11C]KF21213 also
displayed good striatal/cerebellum uptake ratio in rodent (10.5
at 60 minutes) but showed a lower signal to noise ratio in
nonhuman primate brain.121,123 Among the latter 2 xanthene-
derived PET radioligands, [11C]TMSX has been the most
suitable radiotracer for mapping the A2ARs and exhibited the
highest binding potential in the striatum.120 Currently,
[11C]TMSX is the most broadly used PET imaging radioligand
for visualization of A2A receptor in the brain and therefore is
considered the gold standard for brain imaging of the A2A
receptors.121,122 A major consideration when using this tracer
is the fact that dosing and blood sampling need to be performed
under dimmed light due to [11C]TMSX photoisomerization.
To overcome the photoisomerization issue inherent with
xanthene radiotracer [11C]TMSX, a potent, selective, and
reversible nonxanthene A2AR antagonist SCH442416 was radi-
olabeled to produce [11C]SCH442416 and exhibited a good
striatum/cerebellum uptake ratio with slow rate of metabolism
in rat.124 In rhesus monkeys, [11C]SCH442416 was rapidly
accumulated in the brain, with twice as much radioactivity
concentration in the striatum than in the cerebellum, but it
showed a high nonspecific binding activity in monkey brain.124
[11C]SCH442416 has been used to study receptor occupancy
and involvement of striatal A2ARs in the brain of PD patients
with dyskinesia.125,126 Both A2ARs antagonists [
11C]TMSX
and [11C]SCH442416 have already been used in multiple stud-
ies in human.122,124 Preladenant, a PD drug, was also
Table 1. Adenosine A1 Receptor PET Ligands for CNS Studies.
Receptor PET ligand Affinity (nM) Status References
A1R [
11C]KF15372 3.0 (Ki) Exhibited high fraction of nonspecific binding that limited its use in preclinical evaluation
of the A1 receptor.
83
A1R [
11C]MPDX 4.2 (Ki, r) Used to study A1R function in patients with AD. Studied in patients with TBI and in
patients with early stages of PD. Currently, the most widely used PET agent for
imaging the A1R in human brain.
85-87
A1R [
11C]FR194921 4.96 (Ki, r)
2.91 (Ki, h)
Showed acceptable BBB permeability, but relatively low specific binding in the rodent
brain that limited its further use.
89,90
A1R [
11C]MMPD 0.49 (Ki, r)
0.8 (Ki, h)
Exhibited an A1R partial agonist activity. Showed BBB permeability. Currently under
evaluation in sleep mechanisms.
91
A1R [




Used to study sleep deprivation in humans. Fast metabolic degradation. An inverse
agonist of the A1 receptor.
84,93-96
A1R [
18F]CBCPM 8.86 (Ki) Exhibited low nonspecific binding. Metabolic degradation rate similar to [18]CPFPX.
84
A1R [
18F]CPMMCB 3.73 (Ki) Exhibited low nonspecific binding. Metabolic degradation rate similar to [18]CPFPX.
84
Abbreviations: AD, Alzheimer disease; A1R, adenosine A1 receptor; BBB, brain–blood barrier; CNS, central nervous system; h, human; m, mice; PD, Parkinson
disease; PET, positron emission tomography; r, rat.
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radiolabeled with 11C to produce [11C]Preladenant.126-128 Stud-
ies of this PET tracer in the brain of monkey showed an uptake
that is consistent with the distribution of A2ARs with highest
uptake in the putamen and the caudate, respectively.128 The
lowest uptake of [11C]Preladenant was observed in the cerebel-
lum. Estimated binding potential values of [11C]Preladenant
with different scan durations were similar (4.3-5.3 in A2AR-
rich regions).128 Preinjection with nonradiolabeled Preladenant
reduced the tracer uptake in regions rich in A2AR and pretreat-
ment with caffeine reduced tracer uptake in the striatum in a
dose-dependent manner. [11C]Preladenant PET is a suitable
tool to study A2AR occupancy in the brain.
128 The regional
distribution of [11C]Preladenant PET is consistent with known
A2AR densities in the brain.
126
[18F] PET radio ligands of adenosine A2AR. Few
18F PET radioli-
gand derivatives of potent and selective A2AR antagonist
SCH442416 were developed for imaging of the A2ARs. These
PET ligands include [18F]MRS5425 ([18F]-FESCH),129,130
[18F]-FPSCH,130 and [18F]MNI-444131 as shown in Figure 5.
The A2AR-mediated uptake of [
18F]MRS5425 was higher in the
striatum of the 6-OHDA lesion-induced rats compared to that
of the normal rats, making [18F]MRS5425 a suitable PET
radiotracer for imaging of PD patients.129
A fluoropropyl analog [18F]-FPSCH was also developed and
studied for mapping of the A2A receptors expression in rat
brain.130 Both [18F]-FESCH and [18F]-FPSCH showed similar
striatum/cerebellum ratios post injection as well as reversible
binding in the brains of rat.130 However, dynamic PET imaging
for 60 minutes, under baseline and blocking conditions,
demonstrated [18F]MRS5425 ([18F]-FESCH) to be the most
suitable 18F PET radioligand for quantifying A2A receptor
expression in rat brain.130
Another highly potent nonxanthene 18F PET radioligand
analog of SCH442416, [18F]MNI-444 (Ki ¼ 2.8 nM, human
recombinant A2ARs) was developed to noninvasively monitor
Figure 4. Structures of the adenosine A2A receptor [
11C] PET radioligands: [11C]TMSX, [11C]KF21213, [11C]SCH442416, and [11C]Prela-
denant. PET indicates positron emission tomography.
Figure 5. Structures of the adenosine A2A receptor [
18F] PET radioligands: [18F]MRS5425 ([18F]-FESCH), [18F]-FPSCH, and [18F]MNI-444. PET
indicates positron emission tomography.
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A2A receptor densities and functions in the brain of patients
with PD.131 [18F]MNI-444 radioligand has shown high uptake,
rapid kinetics, and high target/nontarget ratios in the brain,
consistent with A2A receptor distribution.
131,132 Thus far,
[18F]MNI-444 has turned out to be a superior imaging tracer
among all the 18F PET radioligands for studying and mapping
the A2AR in the brain.
133 A list of all A2A receptor PET radi-
oligands is presented in Table 2.
P2X Receptors and Functions in the CNS
P2X receptors (P2XRs) are a family of 7 fast-acting subrecep-
tors P2X1 to P2X7. These nonselective cation-gated channels
receptors exhibit high Ca2þ permeability upon activation by
extracellular ATP.134,135. P2X receptors are widely distributed
on non-neuronal and neuronal cells and participate in numerous
physiological as well as pathophysiological processes.15 Sev-
eral studies have suggested the change in P2XRs expression
under neuroinflammatory, nerve transmission, and pain sensa-
tion conditions.136 Activation of some P2XRs has been asso-
ciated with various pathological disorders of CNS including
neuroinflammation and neurodegeneration.36
With the exception of P2X7R that is only activated by high
concentration of ATP (hundreds of mM), other P2X receptor
subtypes are usually activated at high nM to low mM ATP
concentration.10,11. In the CNS, P2XRs participate in modula-
tion of neurotransmission, neuron-glia communication,
inflammation, and apoptosis.136-139 Adenosine 50-tripho-
sphate released under physiological conditions modulate
synaptic plasticity by acting on P2X receptors via Ca2þ-
dependent interaction with the NMDA receptors that facilitate
LTP in the hippocampus.140 In general, overexpression of the
P2X3, P2X4, and P2X7 receptors have been detected in CNS
disorders and their antagonists could potentially be useful
therapies for the treatment of CNS diseases including
neurodegeneration and brain injuries.6,136,141 Among sub-
types of the P2XRs, P2X7R has been the focus of many stud-
ies as a therapeutic target for treating brain disorders.142
Herein, we focus on 3, P2X3, P2X4 and P2X7, receptors and
review their existing PET radioligands.
P2X3 Receptor and Functions in the CNS
P2X3 receptors, either as a homomeric P2X3 or a combination
of P2X2-P2X3 receptors, are primarily expressed on nocicep-
tive sensory neurons143 and mediate the ATP nociceptive sig-
naling.144 In the spinal cord, released ATP from injured cells
facilitates glutamate release from primary afferent neurons by
its action at the presynaptic P2X3 receptors.
144,145 P2X3 knock-
out animals have shown to exhibit a reduction of activity of
afferent nerves and nociceptive signaling,146 and P2X3 receptor
expression downregulation by antagonist A-317491 has
resulted in reduced mechanical hyperalgesia and neuropathic
pain,147,148 supporting the effect of ATP on peripheral nerve
afferents.146
Thus far, few antagonists of P2X3 and P2X2/3 have been
identified. One of them, A-317491, has shown to reduce
mechanical allodynia and thermal hyperalgesia following
chronic nerve constriction.149,150 AF-353 is another P2X3
receptor antagonist that has shown similar potency for human
and rat recombinant P2X3 homotrimers (IC50¼ 8.7 and IC50 ¼
8.9 nM, respectively).151 A prodrug version of AF-353, (RO-
51), has been developed to treat urological dysfunction and
chronic pain.152 A recently marketed P2X3R antagonist, gefa-
pixant (AF-219, MK-7264), is used for reduction of exagger-
ated, persistent, and frequent urge to cough as a result of
hypersensitized sensory neurons, triggered by injury or infec-
tion.153-155 Recently, a series of 5-hydroxy pyridine derivatives
were synthesized and evaluated for their activities at hP2X3
receptors.156 One of the compounds in this series, prodrug
Table 2. Adenosine A2A Receptor PET Ligands for CNS Studies.




5.9 (Ki, r) Used widely and considered a gold standard PET ligand for mapping A2R. Has been
studied in human subjects and in patients with PD, HD, and MS.
25,121,122
A2AR [
11C]KF21213 3.0 (Ki, r) Possessed high in vitro selectivity (A2A/A1 >3300). Good striatal/cerebellum uptake
ratio in rodent, but lower signal to noise ratio in nonhuman primate brain.
25,123
A2AR [
11C]SCH442416 0.048 (Ki, h)
0.5 (Ki, r)
Studied in patients with PD who suffer from the levodopa-induced dyskinesia. The first
suitable nonxanthine A2AR PET ligand.
25,124
A2AR [
11C]Preladenant 1.1 (Ki, h)
2.5 (Ki, r)






12.4 (Ki) Used for quantifying A2A receptor expression in the rat brain and showed higher
concentration in the striatum of the 6-OHDA lesion induced in rats, possibly a
suitable PET radiotracer for imaging of PD.
129,130
A2AR [
18F]-FPSCH 53.6 (Ki) Propyl analog of [
18F]FESCH and very similar in property, but less suitable PET. 130
A2AR [
18F]MNI-444 2.8 (Ki, h) Exhibited superior property for studying and mapping the A2AR in the brain. Used as
PET and SPECT radiopharmaceutical to study human brain. Showed high uptake,
rapid kinetics, and high target/nontarget ratios in the brain, consistent with A2A
receptor distribution.
25,131-133
Abbreviations: A2AR, adenosine 2A receptor; CNS, central nervous system; h, human; HD, Huntington disease; m, mice; MS, multiple sclerosis; 6-OHDA, 6-
hydroxydopamine; PD, Parkinson disease; PET, positron emission tomography; r, rat.
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28, has shown antiallodynic activity in spinal nerve ligation and
chemotherapy-induced peripheral neuropathy in rats.156 This
and other data on the P2X3R antagonists indicate that targeting
the P2X3 receptors could be a promising treatment for neuro-
pathic pain. Thus far, there is no identified PET radioligand for
evaluation of the P2X3 receptors, to the best of our knowledge.
P2X4 Receptor and Functions in the CNS:
P2X4 receptor, the first identified P2X receptor, is widely
expressed in peripheral nervous system and CNS.157 P2X4
receptors are one of the most abundantly expressed functional
purinergic receptors found on glial cells and most neurons17,158
and are upregulated on activated microglia after brain and
spinal cord injuries.159 Similar to P2X7R, P2X4R facilitate ion
efflux through cell membrane and induces activation of inflam-
masomes.137 Supporting evidences indicate that P2X4 recep-
tors physically couple with GABAA receptors as well as with
the P2X2 receptors and this cross talk may play a role in reg-
ulating synaptic signaling and plasticity of neurons.160 Alcohol
abuse is known to enhance neuroinflammation through P2X4Rs
activation161 and there are suggestions of implication of
P2X4Rs in tolerance to morphine and hyperalgesia induction
by morphine.161,162 P2X4 receptors are upregulated in TBI
6, in
acute experimental encephalomyelitis (EAE) rodent model of
multiple sclerosis17 and following hypoxia and ischemia
events.163 In neurons, P2X4R has shown to stimulate activation
of the inflammasome caspase-1 resulting in cytokines IL-18
and IL-b release, and in P2X4R knockout mice, impaired
inflammasome signaling was reported to couple to the reduc-
tion of IL-b level.164 Inhibition of P2X4 receptors by antago-
nists prior to cerebral ischemia has resulted in an attenuation of
the neuroinflammation response and health of neuronal tis-
sue.165 Additionally, P2X4 receptor upregulation has been
reported in several rodent models including mechanical allo-
dynia,14 superoxide dismutase 1-mutation models of ALS,166
EAE model of multiple sclerosis,17 post spinal cord injury,164
formalin-induced inflammatory pain,167 TBI,168 and ische-
mia.165 These data support the central role that P2X4 receptors
play in coordinating the microglial response to cellular injuries
and/or diseases.
Therefore, P2X4 receptor antagonists might have potentials
for the treatment of neuropathic pain,23 epilepsy, stroke, mul-
tiple sclerosis, and neurodegenerative diseases such as PD and
AD.159,169 Paroxetine, a selective serotonin reuptake inhibitor,
has shown to behave as an allosteric antagonist of P2X4Rs at
high concentrations (IC50 ¼ 2.45 mM, rat, and IC50 ¼ 1.87 mM,
human).170 Thus far, attempts to identify potent and selective
antagonist of P2X4Rs have resulted in the discovery of allos-
teric ligands with low potency and poor aqueous solubility.
Among these antagonists is the benzodiazepine derivative 5-
BDBD (IC50 ¼ 0.5 mM)171 and its analogs172 that possessed
allosteric antagonism, but low potency at P2X4R.
172 The urea
derivative BX-430 was another allosteric P2X4 receptor
antagonist with low potency (IC50 ¼ 0.54 mM).173 An addi-
tional allosteric P2X4Rs antagonist is the high lipophilic and
poor soluble carbamate PSB-12054 with good selectivity and
reasonable potency at human P2X4Rs but much less potency at
rat and mice P2X4Rs.
174 An analog of PSB-12054, PSB-12062
with better solubility, was developed later and showed equal
potency at human, rat, and mouse and good selectivity for
P2X4R versus P2X1, P2X3, and P2X7 receptors.
175 Recently,
a new diazepine antagonist NP-1815-PX with reasonable
potency and selectivity at P2X4Rs (IC50 ¼ 0.26mM, hP2X4R,
concentration dependent)176 has shown an antiallodynic effect
and suppression of mechanical allodynia in mice with trau-
matic nerve damage without affecting acute nociceptive pain
and motor function, suggesting that microglial P2X4Rs could
potentially act as an important target for treating chronic
pain.176 Nippon Chemiphar has reported the discovery of yet
another potent antagonist of the P2X4Rs, NC-2600 for the
treatment of neuropathic pain. Phase I evaluation of NC-2600
has been completed and phase II evaluation is underway. NC-
2600 is believed to be the first-in-class candidate to control
pain by targeting glial cells. NC-2600 is currently under
safety/tolerability studies. To our best knowledge, lack of
highly potent P2X4Rs ligands has limited efforts to develop
PET ligand for this receptor.
P2X7 Receptor and Functions in the CNS
P2X7R is regarded as an important silent receptor as its expres-
sion is only upregulated when ATP concentration increases to a
high level,177 suggesting the high relevance of P2X7Rs in
pathological conditions.178 P2X7Rs are expressed on presynap-
tic neurons, astrocytes, and oligodendrocytes, but its highest
concentrations is expressed on microglia where it releases pro-
inflammatory cytokine IL-1b, a key mediator of chronic
inflammation and chronic pain.6,178 Several studies of the
P2X7 receptors have shown involvement of this receptor in
animal models of neuroinflammatory diseases including
AD,137,179,180 PD,181 HD,182 FD,1 ALS,183 MS,184 TBI,15 cere-
bral ischemia,6 epilepsy,185 depression,186,187 anxiety, and
bipolar disorders.178 Astrocytic P2X7Rs expression has also
shown to be involved in the neurotoxic phenotype model of
ALS.188
Stimulation of P2X7Rs by high level of ATP (hundreds of
mM) produces a large transmembrane pores, permeable to large
molecular sizes of up to 900 Da, promoting further increase in
extracellular ATP release that can lead to activation of caspases
and result in cell death.189 P2X7 receptor expression in the CNS
could be increased with systemic administration of bacterial
lipopolysaccharide (LPS), providing a realistic mechanism
similar to systemic infection in the brain.6 Genetic deficiency
and pharmacological inhibition of P2X7 receptors have shown
to attenuate hyperactivity induced by amphetamine in the
model of manic bipolar disorder.190 Mood stabilizer drugs such
as lithium and valproate reversed ATP-induced cell death in the
hippocampus, an action that is probably mediated by P2X7
receptors.191,192
Discovery of a number of potent and selective P2X7Rs
antagonists has been instrumental in studying the receptor in
8 Molecular Imaging
human and rodent. Some of these ligands including
AZD9056193 and CE-224535194 were developed for the treat-
ment of inflammation but failed to exhibit benefits in
patients.194 Other existing and understudy ligands of the
P2X7 receptors include A438079, A740003, A804598,
A839977, AZ1060612, AZ11645373, GSK1482160, and
GW791343.9,195
Some P2X7 receptor antagonists were specifically devel-
oped to study disorders of the CNS. These are the brain
penetrant benzamides GSK1482160,196 JNJ-42253432,197
JNJ-47965567,198 triazoles JNJ-54232334 and JNJ-
54140515,199 JNJ-54166060,200 JNJ-54173717,201 JNJ-
54175446,202 and JNJ-55308942.203 These molecules have
demonstrated P2X7 receptor antagonist activities in rodent and
human. Three of these molecules, GSK1482160, JNJ-
54175446, and JNJ-55308942, have already moved into clin-
ical trials for evaluation of the disorders of CNS.187
Association of P2X7R activation with pro-inflammatory
phenotype of microglia in CNS diseases makes P2X7R an inter-
esting and valuable biomarker of inflammation.9 Development
of useful PET radioligands for imaging the P2X7Rs in CNS can
potentially enable studies of the pharmacology and functional
role of this receptor in neuroinflammation and evaluate the
effect of therapeutic agents in treating neuroinflammatory and
neurodegenerative diseases. Fortunately, an ample number of
potent and selective P2X7R ligands has presented opportunities
to develop a few 11C and 18F PET radioligands of the receptor
as described herein.24,204
[11C] PET radioligands of P2X7R. Several antagonists of the
P2X7R have been radiolabeled with
11C for evaluation of the
receptor expression and function as shown in Figure 6. The
selective P2X7R antagonist A-740003 (IC50 ¼ 18 nM, rP2X7R
and IC50 ¼ 40 nM, hP2X7R) was radiolabeled with 11C to
produce [11C]A-740003,205 but showed low biodistribution and
poor brain permeability.205 The first brain penetrable 11C PET
radioligand for quantification of P2X7R expression in the brain
was [11C]JNJ-54173717. This tracer showed high potency in
humanized rat P2X7R (IC50 ¼ 4.2 nM, hP2X7R)206 and excel-
lent uptake in the hP2X7R overexpressing striatum area that
was reduced by pretreatment with nonradioactive antagonists
JNJ-54173717 and JNJ-42253432, suggesting selective P2X7R
binding of this radiotracer in the brain.24 Additionally,
[11C]JNJ-54173717 displayed high brain uptake in rhesus mon-
key, an indication of BBB penetrability to study receptor
expression levels in neurodegenerative disorders in humans.206
Another potent P2X7 receptor antagonist, benzamide
GSK1482160 was also radiolabeled with 11C to produce PET
radioligand [11C]GSK1482160 (Ki ¼ 2.63 nM, IC50 ¼ 3 nM,
hP2X7 and Kd ¼ 1.15 + 0.12 nM, hP2X7R).207-209 Evaluation
of [11C]GSK1482160 in mouse model of LPS-induced neuroin-
flammation showed increased uptake of 3.6-fold compared
with saline-treated mice in all studied organs (2.9- to 5.7-
fold).208 In the EAE rat model of MS, [11C]GSK1482160
uptake was high in rat lumbar spinal cord and the highest
uptake was measured at the EAE peak stage.209 Micro-PET
studies of [11C]GSK1482160 in rhesus monkey has shown high
tracer retention and a homogeneous brain distribution.209 All of
these studies strongly correlated the [11C]GSK1482160 uptake
with the P2X7 R overexpression on activated microglia and its
participation in neuroinflammation.209 Another 11C PET radi-
oligand of P2X7 R antagonist was developed by radiolabeling
of the SMW139 (Ki ¼ 32 nM, hP2X7R)210 and was evaluated
in a humanized rat model to study the expression of P2X7R in
striatum.210 Even though [11C]SMW139 did not detect over-
expression of the P2X7 R in postmortem brain of patients with
AD,210,211 this PET radioligand has entered clinical evaluation
in patients with MS and is currently the first in human to study
neuroinflammation in patients with MS.210,212
[18F] PET radioligands of P2X7R. Thus far, there are reports of 3
known 18F radioligands for evaluation of the P2X7R expres-
sion as shown in Figure 7. An analog of a potent P2X7R
antagonist A-804598 was radiolabeled with 18F to yield
[18F]EFB that showed high affinity for human and rat
P2X7R.
213 However, this PET tracer suffered from a low
brain uptake in both healthy and LPS-treated rats that lim-
ited its application for brain imaging of the receptor.213
Another PET radioligand [18F]JNJ-64413739 was developed
by 18F radiolabeling of a potent and selective P2X7 R
antagonist JNJ-64413739 (Ki ¼ 2.7 nM, rat cortex, Ki ¼
15.9 nM, hP2X7R). [18F]JNJ-64413739 has shown to be an
effective PET ligand for mapping of P2X7R in human
brain.214 The PET imaging studies with [18F]JNJ-
Figure 6. Structures of the P2X7 receptor [
11C] PET radioligands: [11C]A-740003, [11C]JNJ-54173717, [11C]GSK1482160, and [11C]SMW139.
PET indicates positron emission tomography.
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64413739 in nonhuman primate showed engagement of the
tracer with the P2X7R. In vitro blocking experiments of
[18F]JNJ-64413739 with 2 known P2X7R antagonists
demonstrated inhibition of the tracer binding to rat brain
tissue sections in a dose-dependent manner.214-216 While
[18F]JNJ-64413739 may be a useful tool for imaging of
neuroinflammation, lack of a reference region in image
analysis (ie, similar to TSPO) might hinder its use as an
optimum PET radiotracer for detection of neuroinflamma-
tion.214,217 Most recently, our team has synthesized a novel
18F radioligand [18F]IUR-1601, the fluoroethyl analog of
GSK1482160.218 [18F]IUR-1601 has been successfully eval-
uated in vitro and is currently under evaluation in 5XFAD
animal model of AD. A list of all P2X7 receptor PET radi-
oligands is presented in Table 3.
P2Y Receptors and Functions in the CNS
The metabotropic P2Y receptors are a family of GPCRs with 8
subtypes: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and
P2Y14, with ubiquitous expression and effect in body.
18,219 In
the CNS, P2Y receptors are localized on neurons, microglia,
astrocytes, and oligodendrocytes where they have important
physiological roles in glial-cell communication, neurotrans-
mission, and neurogenesis.220,221 The hippocampus expresses
P2Y1, P2Y2, P2Y4, P2Y6, and P2Y12 receptors in addition to all
the P2X receptor subtypes.67
In contrast to the ion channel P2X receptors, P2YRs are
activated by several endogenous ligands including the adenine
nucleotides: ADP (acting on P2Y1, P2Y12, and P2Y13) and
ATP (acting on P2Y2 and P2Y11), and the uridine nucleotides
Figure 7. Structures of the P2X7 receptor [
18F] PET radioligands: [18F]EFB, [18F]JNJ-64413739, and [18F]IUR-1601. PET indicates positron
emission tomography.
Table 3. P2X7 Receptor PET Ligands for CNS Studies.
Receptor PET ligand Affinity (nM) Status References
P2X7R [11C]A-740003 18 (IC50, r)
40 (IC50, h)
Showed low brain uptake and a moderate metabolic rate. 205
P2X7R [
11C]JNJ-54173717 1.6 + 0.1 (Ki, r)
4.2 (IC50, h)
7.6 (IC50, r)
Entered rat brain and showed excellent uptake in the human P2X7R




11C]GSK1482160 2.63 + 0.6 (Ki)
1.15 + 0.12 (Kd)
3 (IC50, h)
Possessed high P2X7 selectivity and good blood–brain barrier permeability.
Studied in mouse model of LPS-induced neuroinflammation and EAE rat
model of MS. Showed a high tracer retention and a homogeneous brain
distribution in rhesus monkey. In preclinical evaluation.
196,207-209
P2X7R [
11C]SMW139 32 + 5 (Ki, h)
24.5 + 5.5 (IC50, h)
158 + 44 (IC50, m)
Entered clinical trial to study neuroinflammation in patients with MS. 210-212
P2X7R [
18F]EFB 2.88 (Ki, h)
36.1 (Ki, r)
547 (Ki, m)
Exhibited low brain uptake due to limited compatibility of the
cyanoguanidine moiety with BBB entry in rats. Limited solubility.
213
P2X7R [
18F]JNJ-64413739 15.9 + 2.0 (Ki, h)
2.7 + 1.1 (Ki, r)
1.0 + 0.2 (IC50, h)
2.0 + 0.6 (IC50, r)
Showed dose-dependent competitive binding with JNJ-54175446 in monkey
PET studies. A potential imaging biomarker of central neuroinflammation.





Evaluated in in vitro assays and is currently under evaluation in 5XFAD animal
model of AD.
218
Abbreviations: AD, Alzheimer disease; BBB, brain–blood barrier; CNS, central nervous system; h, human; LPS, lipopolysaccharides; m, mice; MS, multiple sclerosis;
PET, positron emission tomography; P2X7R, P2X7 receptor; r, rat.
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UTP (acting on P2Y2 and P2Y4), UDP (acting on P2Y6), and
the UDP-glucose (acting on P2Y14).
222
Several studies have revealed that during brain injury and
under pathological conditions, neurons,223 astrocytes,189 and
microglia224 release high concentration of ATP that acts as a
neuromodulator of the P2Y receptors.134,225 P2Y receptor acti-
vation then induces fast synaptic transmission through postsy-
naptic P2X receptors in the brain.135 Therefore, P2Y receptors
affect the release of number of neurotransmitters225 through
actions on calcium influx.226
The P2Y receptors, individually or in combination, partici-
pate in many biological conditions. P2Y1R has a complex role
in modulation of DA release, even though there is no evidence
of its existence in the dopaminergic terminals of the prefrontal
cortex.227,228 P2Y1, P2Y12, and P2Y13 receptors specifically
block the release of noradrenaline in the spinal cord,229 the
hippocampus,230 and in the cortex,228 while these same recep-
tors inhibit the release of serotonin in the cortex.231 P2Y1,
P2Y2, P2Y4, P2Y12, and P2Y13 receptors have also shown to
inhibit the release of glutamate in the spinal cord,226 the hip-
pocampus synapses, and the cerebral cortex.221 P2Y12 receptor
is known as a protective receptor that stimulates microglial
migration toward neuronal damage.16 Functional studies have
demonstrated the involvement of P2Y receptors in seizure
pathology, as well.232
Some of the P2Y receptors have prominent roles in neuro-
degenerative diseases. For example, during neuronal injuries,
P2Y2, P2Y4, and P2Y6 receptors regulate the phagocytic activ-
ity of microglia upon leaked UTP and UDP from injured hip-
pocampal cells.233 Microglia execute the uptake of cellular
debris specifically through P2Y6 receptor.
233 P2Y1, P2Y4, and
P2Y12 are prominent P2YRs in the brain and represent favor-
able targets for treating neuroinflammatory diseases and neu-
rodegenerative disorders including AD.46,226
Activation of some P2YRs has shown to inhibit the excita-
tory transmission mediated by postsynaptic NMDA receptors
and increase the inhibitory action of the GABAA receptors
prompting LTP.226,234 In the CA1 region of hippocampus,
released ATP from astrocytes has shown to result in LTD of
synapses from neighboring neurons via activation of the pre-
synaptic P2Y receptors, indicating participation of ATP from
activated astrocytes in this form of plasticity.140 In a specific
region of the brain, the medial habenular nucleus that is
involved in depression, stress, and nicotine withdrawal234,235
an application of UTP or UDP resulted in LTP of a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptor-mediated currents, apparently through activation of
presynaptic P2Y4R.
226
There has been suggestions that activation of P2Y2 and
P2Y4 receptors may be useful in treating neurodegenerative
diseases.18,221 Studies of rat primary cerebellar neurons has
provided evidence that P2Y13 receptor activation protected
neurons against oxidative stress-induced death.236 P2Y1 recep-
tor has specifically emerged as a new target for treating cog-
nitive dysfunction in CNS.226,237,238
Overall, investigations of the P2Y family receptors have
been challenging due to the lack of potent, selective, and
high-specific-radioactivity PET radioligands for these recep-
tors. Herein, we present the subfamily of P2Y receptors and
their ligands that are known to have important functions in
the CNS.
P2Y1 Receptor and Functions in the CNS
P2Y1 receptor is one of the most abundant P2Y receptor sub-
type in brain tissues with large expression on neurons of the
cerebellum,237 cerebral cortex, and ischemia-sensitive regions
of the hippocampus that is predominantly implicated in AD.239
P2Y1R is also expressed on oligodendrocytes and astrocytes in
the brain and optic nerves.240,241 Human P2Y1R is activated by
ADP (EC50 ¼ 10 nM),220,221 and ADP activation of the recep-
tor induces platelet activation making this receptor as an impor-
tant antithrombotic drug target.242 Like P2X7 receptor, P2Y1
receptor also mediates activation of microglia after brain inju-
ries and insult.243
There are reports of P2Y1 receptor upregulation in CNS
under pathological conditions such as mechanical injury,244
ischemia,245 and neurodegeneration.246 Additionally, hyperac-
tivity of astrocytic P2Y1 receptors have been detected in animal
models of AD246,247 and increased expression of the receptor
has been observed in hippocampus and cortex of postmortem
brain sections in patients with AD.248 P2Y1R is also upregu-
lated after stroke and TBI and inhibition of the receptor has
been shown to reduce cognition deficit resulted from these
conditions.249 Indeed, antagonists of the P2Y1 receptor have
shown to reduce neuronal injury and improve spatial memory
in rat model of TBI.250,251
Inhibition of astrocytic P2Y1R has resulted in cytokine and
chemokine transcriptional suppression and brain protec-
tion.247,250 Blocking of hippocampal P2Y1 receptors has shown
to enhance synaptic signaling and might be responsible for
promotion of antioxidant mechanism that consequently results
in pro-survival pathways.249,252 P2Y1R antagonists have also
shown to mediate and upregulate the oxidoreductase enzymes
by increasing tolerance to hydrogen peroxide.253 A recent
study has shown that P2Y1 agonist MRS2365 initiated nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-kB)
release after stroke and enhanced neuroinflammatory
responses, while P2Y1 receptor antagonist MRS2179 attenu-
ated inflammation and reduced the infarct size.250,251 Further-
more, P2Y1 antagonist has shown to help patients with
schizophrenia to experience reduction in unnecessary informa-
tion and noise entering their brain.254
Ironically, there is an evidence that P2Y1Rs may also
promote axonal elongation to offset the neurotoxic effects
of neurofibrillary tangles and have a neuroprotective effect
in patients with AD.255 Nevertheless, there are still more
supporting data that P2Y1R antagonist could potentially be
appropriate candidates for the treatment of neurodegenera-
tive diseases.247-249
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PET radioligand of P2Y1R. Overall, investigation of the P2Y fam-
ily receptors has been challenging due to the absence of potent,
selective, and high-specific-radioactivity PET radioligands.
Recently, a highly potent (IC50 ¼ 10 nM) P2Y1R antagonist
(compound 18) was identified and radiolabeled with [18F]
([18F]18) as shown in Figure 8. Although [18F]18 exhibited fast
in vivo metabolism, its high potency and unique allosteric
binding mode has provided an opportunity to investigate it as
a potential PET tracer for mapping the P2Y1 receptor.
256 Addi-
tionally, highly potent, selective, and high specific radioligand
[32P]MRS2500 has been used successfully to measure human
P2Y1 receptor expression in Sf9 insect cell membrane.
257
P2Y2 Receptor and Functions in the CNS
One of the most studied receptors in this family is the P2Y2R,
with a wide distribution in all cells in human body and partic-
ularly in immune cells.258 In the brain, P2Y2 receptor is
expressed on neurons, microglia, and astrocytes.12,259 Under
normal brain conditions, there is a low expression of P2Y2R
on neurons, but it can be upregulated to exert neuroprotective
effects against the release of pro-inflammatory cytokine IL-1b
as a result of P2X7R expression on activated microglia.
260 In
the AD mouse model TgCRND8, genetic deletion of P2Y2
receptor has shown to enhance early AD pathology, while acti-
vation of the receptor enhanced phagocytosis and degradation
of the Ab peptide.261 Furthermore, activation of P2Y2R has
proven to result in degradation of amyloid precursor protein
by a-secretase, yielding to soluble APPa peptide that prevented
production and accumulation of the neurotoxic Ab1-42.
262,263 In
studies that compared brain neocortex and parietal cortex of
postmortem patients with AD to those of the normal aged con-
trols, the low level of P2Y2R expression was associated with
neuropathology and synapse loss in patients with AD,263 pre-
senting additional support for neuroprotective function of
P2Y2R in AD pathology.
264 Additionally, activation of the
P2Y2R has shown to promote neurite outgrowth.
265 These stud-
ies suggest that loss of neuroprotective functions of P2Y2R
might contribute to disease pathogenesis in AD, and therefore,
targeting the P2Y2Rs with agonist might be a promising strat-
egy to boost neuroprotection in neurodegenerative diseases.
P2Y2R is equally activated by ATP and UTP (EC50 ¼ 0.3-3
mM),221 suggesting its close proximity to conditions such as
inflammation and apoptosis.258 All known agonists of P2Y2R
are derivatives of ATP and UDP (UDPpS, MRS2698,
INS37217, INS48823, a,b-methylene-UDP, 5-bromo-UTP,
PSB-1114). One such agonist INS365 (diquafosol, EC50 ¼
100 nM) has been approved as an ophthalmic solution for the
treatment of dry eye syndrome.266 PSB1114 is another known
P2Y2R agonist that possesses 60-fold selectivity over the
P2Y4R or the P2Y6R.
267 Two of the P2Y2R agonists INS37217
and MRS2698 are currently in clinical trials for treating cystic
fibrosis.258 Thus far, there are no reports of any PET radioli-
gand for imaging of this receptors.
P2Y4 Receptor and Functions in the CNS
The P2Y4R is present in all cells of the brain, including neu-
rons,268 astrocytes,269 and microglia.270 However, the func-
tional role of the receptor is still ambiguous. It is believed
that P2Y4 R might complement the P2Y2R since both receptors
are present in glial end feet in vicinity of the blood vessel
walls.271 Human P2Y4R is stimulated by UTP (EC50 ¼ 73
nM), but not by ATP.272 However, both nucleotides activate
the rat and mouse P2Y4 receptors. In microglia, P2Y4 receptors
are involved in ATP triggered pinocytosis that results in the
uptake of soluble Ab1-42, and either P2Y4 knockdown or ATP
deficiency has shown to decrease this process.273 Hence, in
addition to the P2Y12 receptor-mediated “find me” signal
16 and
the P2Y6 receptor-mediated “eat me” signal,
233 P2Y4 receptors
facilitate “drink me” signal that enables uptake of soluble Ab
by microglia.273 Therefore, activation of P2Y4 receptor in AD
may have a neuroprotective effect possibly through uptake of
Ab1-42.
273,274
Thus far, there has been no report of a selective P2Y4R
agonists or antagonists. Nonselective P2Y agonists UTPgS,275
5-bromo-UTP,276 INS365, INS37217, and INS45973 also exhi-
bit agonist activity for the P2Y4R.
277,278 Recently, an anthra-
quinone derivative was synthesized and showed selective and
noncompetitive antagonist activity at the hP2Y4Rs (IC50¼ 233
nM).279 To the best of our knowledge, there has been no report
of any PET radioligand for mapping of the P2Y4Rs thus far.
P2Y6 Receptor and Functions in the CNS
The P2Y6 receptor is distributed on both immune and nonim-
mune cells and plays an important role in mammalian innate
immunity.280 It is preferentially activated by UDP (EC50 ¼ 15
nM).221 Under conditions that cause neuronal damage or in
response to LPS, UDP leakage from damaged cells facilitates
uptake and removal of cellular debris by activation of the
microglial P2Y6 receptors,
6,281 especially in PD.221 Indeed,
P2X6R is regarded as a potential clinical biomarker of PD and
other neuroinflammatory diseases.282
Additionally, UDP has shown to promote feeding through
activation of P2Y6 receptors in AgRP neurons. These neurons
are known to be involved in systemic insulin resistance which
is an onset of obesity-associated hyperphagia.283 Moreover,




hypothalamic UDP concentrations have shown to be increased
in obesity disorder.283
Inhibition of P2Y6R has proven to be a potential therapeutic
strategy for treatment of neuroinflammation, PD,282 feeding
disorders, and systemic insulin resistance in obesity condi-
tion.283 Potent and selective nonnucleotide P2Y6R antagonist
MRS2578 (IC50 ¼ 37 nM, hP2Y6 R and IC50 ¼ 98 nM,
rP2Y6R) has shown to inhibit UDP-induced phagocytosis and
prevent LPS-induced neuronal loss in mixed neuronal/glial
cultures.284 MRS2578 specifically lacks any antagonist activity
at P2Y1,2,4,11 receptors.
285,286 Recently, a novel selective
hP2Y6R antagonist TIM-38 was reported with low potency
(IC50¼ 4.3 mM).287 TIM-38 could be a useful pharmacological
tool and a starting point for the development of therapeutic
agents against P2Y6 receptor-implicated disease. Activation
of P2Y6R by either its endogenous ligand UDP or selective
agonist MRS-2693 has shown to promote production of pro-
inflammatory cytokines IL-6 and IL-8 and contribute to pha-
gocytosis of neurons.288,289 To the best of our knowledge, there
has been no report of any PET radioligand for mapping of the
P2Y6Rs.
P2Y12 Receptor and Functions in the CNS
P2Y12 receptor is activated by endogenous agonist ADP (EC50
¼ 60 nM).221 It acts as a regulator of blood clotting; therefore,
it is targeted for the treatment of thromboembolisms.290 In
normal brain, P2Y12R expression level is high on M2 type
microglia291 but downregulates under pathological conditions
or after LPS treatment.291,292 Indeed, expression of P2Y12 in
microglia was undetectable 24 hours after injury.16 During
microglial transition from highly ramified to an amoeboid
state, low level of P2Y12 receptors is an indication of the recep-
tor role in early responses of microglia to the brain injury.16
Immunohistochemical studies of postmortem brains from
patients with AD and MS have shown reduction of P2Y12
receptor expression on microglia near the injury sites.291
Therefore, P2Y12 receptor could potentially act as a valuable
biomarker for detecting the activity of human microglia during
CNS pathologies in neurodegenerative diseases.291 P2Y12 is
also expressed on astrocytes of the rat cortex and hippocampal
pyramidal neurons and on oligodendrocytes where is involved
in myelination.271,293
Within the P2Y receptor family, both P2Y12 and P2Y6
receptors233 control microglia activation and migration to
the injury site; however, P2Y12R expression is decreased,
while P2Y6R expression is increased.
294,295 P2Y12 receptor
also participates in a crosstalk with A3R to perform the
process extension of microglia,296 suggesting the nucleo-
tides action on P2Y12 as a primary target to induce micro-
glial chemotaxis early on in response to CNS injury.
Therefore, P2Y12R can potentially be targeted for the treat-
ment of neurodegenerative diseases.16
A wide variety of antithrombotic P2Y12R antagonists such
as ticlopidine (Ticlid), clopidogrel (Plavix), ticagrelor (Bril-
inta), prasugrel (Effient), ticagrelor (AR-C 69931),297 and
MRS-2395298 have been developed for the treatment of platelet
aggregation.269,299 Inhibition of the P2Y12R through knock-
down of expression or by pharmacological inhibitor has
resulted in less neuronal injury.294 The direct effects of the
P2Y12 antagonists on cardiovascular system may indirectly
heal neural injury and CNS diseases.16 Therefore, inhibition
of both P2Y6 and P2Y12 receptors with their antagonists may
prevent phagocytosis of salvageable cells and could be a pro-
mising path in treating neuroinflammation-induced
neurodegeneration.251
PET Radioligand of P2Y12R. Since P2Y12 receptors are the only
identified target exclusively expressed on M2-type microglia,
PET imaging of this receptor could help detect the precise role
of microglial phenotype in each stage of neuroinflammation
and identify stages of the neurodegeneration diseases. Thus,
an antagonist of P2Y12R (sulfonylureas compound 5, with
IC50 ¼ 6 nM)300 was radiolabeled with 11C to produce
[11C]5, as shown in Figure 9 and used as a PET tracer for
evaluation of the P2Y12 receptor
301 function in MS disease
progression.24,302 Unfortunately, [11C]5 was shown to be an
unstable tracer that metabolized rapidly in plasma and in an
ex vivo biodistribution study in rats, and only very low brain
uptake of this radioligand was detected in this study.302 There-
fore, its use for PET imaging of the P2Y12 receptor is not
favored.
P2Y13 Receptor and Functions in the CNS
P2Y13 receptor is one of the most recently identified nucleotide
receptor on neurons.303 Like P2Y1 and P2Y12, P2Y13 receptor
belongs to a group of P2Y receptors responding to endogenous
nucleotides ADP.304 P2Y13Rs are specifically present in cere-
bellar astrocytes, microglia, and granule neurons where they,
and not the P2Y1 receptors, participate in the ADP-evoked
calcium responses with P2Y13 expression higher in microglia
than in the astrocytes.305 In granule neurons, P2Y13 receptors
have been coupled to PI3K/Akt pathway that prevents neuronal
death.304 Additionally, P2Y13-mediated ERK1/2 signaling has
shown to trigger activation of CREB, suggesting an antiapop-
totic act of the P2Y13 receptor against glutamate neurotrans-
mitter toxicity.304 P2Y13 receptors are implicated in the release
of acetylcholine from synapses and play key roles in neuronal
cell differentiation and axonal elongation.305,306
Figure 9. [11C]Radiolabeled P2Y12R PET ligand [
11C]5. PET indicates
positron emission tomography.
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Remarkably, activation of microglial P2Y12 and P2Y13
receptors following inflammation induces the release of para-
crine mediators via upregulation of the P2Y1 and P2Y12 recep-
tors on proliferated astroglia, and upon reduction of
inflammation and microglia phenotype change, both P2Y12 and
P2Y13 have shown to be downregulated on astrocytes.
305
While ADP is the known endogenous agonist of P2Y13
(EC50 ¼ 60 nM),221 2-MeSADP, a nonselective P2Y12/13 ago-
nist, is even more potent at this receptor.271 However, inosine
50-diphosphate sodium salt (IDP) is the preferential selective
P2Y13 agonist with 5-fold more potency for hP2Y13 over the
P2Y12 receptor.
306 Furthermore, IDP with EC50 ¼ 9.2 nM is
more potent at murine P2Y13 than at human P2Y13 (EC50 ¼
552 nM).306 Inosine 50-diphosphate sodium salt is currently
considered as a potent P2Y13 receptor agonist.
306
Among the P2Y13 receptor antagonists, there are some non-
selective P2Y12/13 antagonist including a highly potent P2Y12
antagonist AR-C69931 (IC50 ¼ 0.4 nM) and 2-MeSAMP.221
However, nonnucleoside MRS-2211 is a selective antagonist of
P2Y13 and displays high selectivity over P2Y1 and P2Y12
receptors.307
P2Y14 Receptor and Functions in the CNS
The P2Y14 receptor is preferentially expressed in hematopoie-
tic stem cells of both humans and mice.308 While physiologi-
cal functions of this receptor remain to be established,
expression of the P2Y14 receptor has been detected in immune
cells, suggesting its connotation with inflammation.309 Most
of the data on P2Y14 is associated with its peripheral effects,
but there are indications of its expression in human astro-
cytes310 and rat cortical and cerebellar astrocytes.311
Increased P2Y14 receptor expression in LPS-mediated micro-
glial activation also suggests its role in CNS inflammatory
responses.312 In mice, P2Y14 deficiency has not shown to
carry a noticeable CNS effect under homeostatic conditions,
but showed reduced tolerance to glucose and insulin secretion
deficiency.313 A variety of factors including aging, radiation
therapy, consecutive exposure to chemotherapy, and repeated
bone marrow transplantation have shown to increase senes-
cence in animals lacking P2Y14 receptor.
314
Therapeutic effect of the P2Y14R activation on CNS dis-
eases are not fully elucidated yet. The P2Y14R is activated by
UDP-glucose (EC50 ¼ 80 nM).221 This endogenous ligand is
not prone to hydrolysis and acts as an extracellular pro-
inflammatory mediators.315 UDP also acts as a P2Y14 R ago-
nist, overlapping with the P2Y6R. Several analogs of UDP
including MRS2802 and MRS2905 have exhibited high
potency and selectivity at the P2Y14 over the P2Y6 and other
P2Y receptors.316 Releases of nucleotide-sugars in astrocytes
play an important role in maintaining the normal status of the
cell via P2Y14 receptors.
317
Potential P2Y14R antagonists are dihydropyridopyrimidine
base compound with analogs acting as noncompetitive antago-
nists of the receptor.318 Another set of P2Y14 R antagonists are
naphthoic acid and derivatives that inhibited [3H]UDP binding
to the P2Y14R, suggesting orthosteric antagonism for P2Y14
receptors.319 A selective and highly potent competitive antago-
nist PPTN that was converted to a prodrug has shown to
increase bioavailability allowing further studies of this recep-
tor.320 PPTN has shown to inhibit chemotaxis of human neu-
trophils in cell line expressing P2Y14 receptor.
320 An analog of
Alexa Fluor 488 (AF488), MRS4174 has also exhibited selec-
tivity and a remarkably high binding activity of 80 pM at the
P2Y14R.
320 There has been no report of any PET radioligand
for mapping of the P2Y14Rs.
Concluding Remarks
Existing evidences indicate that chronic inflammation
mediated by modulation of neurons and activation of microglia
and astrocytes plays significant roles in CNS disorders and
specifically in neurodegenerative diseases. Decades of research
toward the discovery and development of treatments for these
diseases, especially the neurodegeneration, while successful to
some extent, still faces hurdles. The probability that some
failed therapies have engaged wrong targets might be a possi-
ble explanation. Preclinical findings suggest that elucidation of
target engagement of drugs in CNS disorders via PET imaging
of the known brain biomarkers can assist to track disease pro-
gression, guide drug development, and monitor therapies for
the treatment of these disorders. This task requires having
access to the number of receptor-selective molecular probes.
Especially in early stage of neurodegenerative diseases, in
addition to evaluation of cerebrospinal fluid and plasma sam-
ples of an individual, PET imaging of pro-inflammatory bio-
marker of the same individual may help identify the causes of
inflammation and potentially assist developing an efficient
translational application of relevant therapeutic interventions.
Purinergic receptors present promising potential for PET ima-
ging of the neurological disorder biomarkers. These receptors
have experienced an exciting journey since the discovery of
their first member in early 20th century. Currently, a number of
11C and 18F PET radioligands of the adenosine, particularly the
A1 and A2A receptors, and the fast synaptic P2X receptor sub-
types, in particular, the P2X7 receptor have helped to elucidate
the expression and functions of these purinergic receptors in
CNS disorders. Despite emerging facts regarding participation
of the P2Y signaling in the brain, their functions are not fully
recognized. This is largely due to lack of availability of selec-
tive nonnucleotide and brain penetrable ligands to be radiola-
beled as PET radiotracer for evaluation of their expression and
functions in the brain. However, a list of P2Y receptor ligands
have been mentioned in this review to enlighten and guide
interested scientists in discovering novel PET ligand for non-
invasive approach to evaluate the P2Y receptor contribution in
the brain disorders and especially the neurodegeneration
diseases.
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